Cargando…

Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer

BACKGROUND: Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small cell lung cancer (NSCLC). The administration of immunotherapy has demonstrated significant efficacy in prolonging the overall survival of patients with KRAS mutation in recent y...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yadong, Peng, Ling, Zhao, Ming, Xiong, Yuanyuan, Xue, Jianchao, Li, Bowen, Huang, Zhicheng, Liu, Xinyu, Yang, Xiaoying, Song, Yang, Bing, Zhongxing, Guo, Chao, Tian, Zhenhuan, Gao, Chao, Cao, Lei, Cao, Zhili, Li, Ji, Jiang, Xu, Si, Xiaoyan, Zhang, Li, Li, Xiaoguang, Zheng, Zhibo, Song, Mengmeng, Chen, Rongrong, Lim, Wan-Teck, Pavan, Alberto, Romero, Atocha, Liang, Naixin, Yang, Huaxia, Li, Shanqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554687/
https://www.ncbi.nlm.nih.gov/pubmed/36248331
http://dx.doi.org/10.21037/tlcr-22-629
_version_ 1784806756565647360
author Wang, Yadong
Peng, Ling
Zhao, Ming
Xiong, Yuanyuan
Xue, Jianchao
Li, Bowen
Huang, Zhicheng
Liu, Xinyu
Yang, Xiaoying
Song, Yang
Bing, Zhongxing
Guo, Chao
Tian, Zhenhuan
Gao, Chao
Cao, Lei
Cao, Zhili
Li, Ji
Jiang, Xu
Si, Xiaoyan
Zhang, Li
Li, Xiaoguang
Zheng, Zhibo
Song, Mengmeng
Chen, Rongrong
Lim, Wan-Teck
Pavan, Alberto
Romero, Atocha
Liang, Naixin
Yang, Huaxia
Li, Shanqing
author_facet Wang, Yadong
Peng, Ling
Zhao, Ming
Xiong, Yuanyuan
Xue, Jianchao
Li, Bowen
Huang, Zhicheng
Liu, Xinyu
Yang, Xiaoying
Song, Yang
Bing, Zhongxing
Guo, Chao
Tian, Zhenhuan
Gao, Chao
Cao, Lei
Cao, Zhili
Li, Ji
Jiang, Xu
Si, Xiaoyan
Zhang, Li
Li, Xiaoguang
Zheng, Zhibo
Song, Mengmeng
Chen, Rongrong
Lim, Wan-Teck
Pavan, Alberto
Romero, Atocha
Liang, Naixin
Yang, Huaxia
Li, Shanqing
author_sort Wang, Yadong
collection PubMed
description BACKGROUND: Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small cell lung cancer (NSCLC). The administration of immunotherapy has demonstrated significant efficacy in prolonging the overall survival of patients with KRAS mutation in recent years. However, the efficacy of immunotherapy in KRAS mutant NSCLC is variable. Analysis of T cell receptor (TCR) repertoire may contribute to a better understanding of the mechanisms behind such differential outcomes. METHODS: A total of 47 patients with KRAS mutant NSCLC were enrolled in this study. Deep sequencing of the TCR β chain complementarity-determining regions in tumor tissue and paired peripheral blood specimens was conducted. Comprehensive analysis of TCR repertoire metrics was performed with different KRAS mutation subtypes and concomitant mutations. Moreover, the associations between TCR repertoire metrics and tumor mutation burden (TMB), as well as programmed death-ligand 1 were explored, respectively. RESULTS: TCR repertoire metrics, including Shannon index, Clonality, and Morisita index (MOI), showed no significant differences among different KRAS mutation subtypes. The similar results were observed between patients with tumor protein p53 (TP53) mutation and those with wild-type TP53. In contrast, although no significant differences were found in Shannon index and Clonality, patients with KRAS/serine/threonine kinase 11 (STK11) comutation showed a significantly higher MOI compared to their STK11 wild-type counterparts (P=0.012). In addition, TCR repertoire metrics were neither associated with TMB nor programmed death-ligand 1 expression in KRAS mutant NSCLC. CONCLUSIONS: This retrospective study comprehensively described the TCR repertoire in KRAS mutant NSCLC. A higher MOI represented more overlap of the TCR repertoire between tumor tissue and paired peripheral blood, indicating distinctive immunological features in NSCLC with KRAS/STK11 comutation.
format Online
Article
Text
id pubmed-9554687
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-95546872022-10-13 Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer Wang, Yadong Peng, Ling Zhao, Ming Xiong, Yuanyuan Xue, Jianchao Li, Bowen Huang, Zhicheng Liu, Xinyu Yang, Xiaoying Song, Yang Bing, Zhongxing Guo, Chao Tian, Zhenhuan Gao, Chao Cao, Lei Cao, Zhili Li, Ji Jiang, Xu Si, Xiaoyan Zhang, Li Li, Xiaoguang Zheng, Zhibo Song, Mengmeng Chen, Rongrong Lim, Wan-Teck Pavan, Alberto Romero, Atocha Liang, Naixin Yang, Huaxia Li, Shanqing Transl Lung Cancer Res Original Article BACKGROUND: Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small cell lung cancer (NSCLC). The administration of immunotherapy has demonstrated significant efficacy in prolonging the overall survival of patients with KRAS mutation in recent years. However, the efficacy of immunotherapy in KRAS mutant NSCLC is variable. Analysis of T cell receptor (TCR) repertoire may contribute to a better understanding of the mechanisms behind such differential outcomes. METHODS: A total of 47 patients with KRAS mutant NSCLC were enrolled in this study. Deep sequencing of the TCR β chain complementarity-determining regions in tumor tissue and paired peripheral blood specimens was conducted. Comprehensive analysis of TCR repertoire metrics was performed with different KRAS mutation subtypes and concomitant mutations. Moreover, the associations between TCR repertoire metrics and tumor mutation burden (TMB), as well as programmed death-ligand 1 were explored, respectively. RESULTS: TCR repertoire metrics, including Shannon index, Clonality, and Morisita index (MOI), showed no significant differences among different KRAS mutation subtypes. The similar results were observed between patients with tumor protein p53 (TP53) mutation and those with wild-type TP53. In contrast, although no significant differences were found in Shannon index and Clonality, patients with KRAS/serine/threonine kinase 11 (STK11) comutation showed a significantly higher MOI compared to their STK11 wild-type counterparts (P=0.012). In addition, TCR repertoire metrics were neither associated with TMB nor programmed death-ligand 1 expression in KRAS mutant NSCLC. CONCLUSIONS: This retrospective study comprehensively described the TCR repertoire in KRAS mutant NSCLC. A higher MOI represented more overlap of the TCR repertoire between tumor tissue and paired peripheral blood, indicating distinctive immunological features in NSCLC with KRAS/STK11 comutation. AME Publishing Company 2022-09 /pmc/articles/PMC9554687/ /pubmed/36248331 http://dx.doi.org/10.21037/tlcr-22-629 Text en 2022 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Wang, Yadong
Peng, Ling
Zhao, Ming
Xiong, Yuanyuan
Xue, Jianchao
Li, Bowen
Huang, Zhicheng
Liu, Xinyu
Yang, Xiaoying
Song, Yang
Bing, Zhongxing
Guo, Chao
Tian, Zhenhuan
Gao, Chao
Cao, Lei
Cao, Zhili
Li, Ji
Jiang, Xu
Si, Xiaoyan
Zhang, Li
Li, Xiaoguang
Zheng, Zhibo
Song, Mengmeng
Chen, Rongrong
Lim, Wan-Teck
Pavan, Alberto
Romero, Atocha
Liang, Naixin
Yang, Huaxia
Li, Shanqing
Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
title Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
title_full Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
title_fullStr Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
title_full_unstemmed Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
title_short Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
title_sort comprehensive analysis of t cell receptor repertoire in patients with kras mutant non-small cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554687/
https://www.ncbi.nlm.nih.gov/pubmed/36248331
http://dx.doi.org/10.21037/tlcr-22-629
work_keys_str_mv AT wangyadong comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT pengling comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT zhaoming comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT xiongyuanyuan comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT xuejianchao comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT libowen comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT huangzhicheng comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT liuxinyu comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT yangxiaoying comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT songyang comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT bingzhongxing comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT guochao comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT tianzhenhuan comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT gaochao comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT caolei comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT caozhili comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT liji comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT jiangxu comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT sixiaoyan comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT zhangli comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT lixiaoguang comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT zhengzhibo comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT songmengmeng comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT chenrongrong comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT limwanteck comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT pavanalberto comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT romeroatocha comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT liangnaixin comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT yanghuaxia comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer
AT lishanqing comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer